Neoleukin Therapeutics, Inc. is a clinical‐stage biotechnology company focused on the design and development of de novo protein therapeutics for the treatment of cancer and immune‐mediated diseases. Leveraging computational protein engineering, the company creates novel cytokine mimetics intended to provide targeted immune activation while minimizing the toxicities associated with natural cytokines. This platform is anchored by proprietary algorithms and structure‐based design tools that enable the rapid generation of therapeutic candidates with optimized stability, affinity and specificity.
The company’s lead candidate, NL-201, is a next‐generation cytokine therapy designed to engage interleukin‐2 and interleukin‐15 receptors on immune effector cells, with the goal of enhancing anti‐tumor responses. NL-201 is currently being evaluated in Phase 1/2 clinical trials in patients with advanced solid tumors and lymphomas. Neoleukin’s pipeline also includes additional preclinical programs targeting autoimmune disorders, where precision immune modulation may offer improved safety and efficacy compared to existing therapies.
Neoleukin Therapeutics was founded in 2019 as a spin‐out from the University of Washington’s Institute for Protein Design and completed a successful initial public offering in mid-2020. Headquartered in Seattle, Washington, the company operates a research and development facility in the Pacific Northwest and collaborates with academic institutions and biopharmaceutical partners to advance its pipeline globally.
Under the leadership of President and Chief Executive Officer David A. Zehnder, Neoleukin is guided by a management team with extensive experience in protein engineering, clinical development and regulatory strategy. As it progresses its novel protein designs through clinical milestones, the company aims to deliver a new class of biologics that address high-unmet needs in oncology and autoimmunity.
AI Generated. May Contain Errors.
